Latest S-1 registration statements

One World Products intends to register for resale up to 21.3 million shares of common stock, including shares issuable to Tysadco Partners, LLC under an equity financing facility.

Digital Locations is shifting its focus to developing technology for high-speed internet delivery from satellites to smartphones and registers 300 million shares for resale by GHS Investments LLC.

ArriVent BioPharma is moving forward with its IPO, offering 8,333,333 shares of common stock with an estimated price range of $17.00 to $19.00 per share.

Pinstripes Holdings has filed a registration statement for the issuance of up to 23,985,000 shares of Class A common stock upon the exercise of outstanding warrants.

Spectral AI, Inc. files an amendment to its S-1 registration statement for the offer and sale of up to 4,050,000 shares of common stock by selling stockholder B. Riley Principal Capital II, potentially raising up to $10 million.

Ozop Energy Solutions is registering up to 1 billion common shares for potential resale by GHS Investments LLC, with the company not receiving proceeds from the resale but from the initial sale to GHS.

Bio-Path Holdings aims to raise capital through a public offering of common stock, pre-funded warrants, and common warrants.

Legato Merger Corp. III, a blank check company, has filed an amendment to its S-1 registration statement for a $175 million initial public offering, aiming to pursue a business combination within the infrastructure, engineering and construction, industrial, and renewables industries.

Liberty Star Uranium & Metals Corp. has filed an amendment to its registration statement for the potential offer and sale of up to 2,490,660 shares of common stock upon exercise of warrants held by Triton Funds, LP.

DT Cloud Acquisition Corporation amends its S-1 filing, detailing registration rights for investors holding Initial Shares, Private Units, Over-Allotment Units, and Working Capital Loan Securities.

Peraso Inc. is launching a public offering of common stock and warrants to raise capital for general corporate purposes, including research and development.

CG Oncology is seeking to raise $289 million through an initial public offering to fund the development and commercialization of its bladder cancer therapeutic, cretostimogene.

Gyrodyne, LLC is launching a rights offering to raise $5 million to support its liquidation strategy, including legal defenses and property entitlement pursuits.

Data443 Risk Mitigation outlines terms for its 2023 Equity Incentive Plan and a public offering of units, including common stock, warrants, and pre-funded warrants.

Microbot Medical offers new preferred investment options and a reduced exercise price to holders in exchange for exercising existing options.

Blue Star Foods Corp. has filed an amendment to its registration statement for the potential offer and resale of up to 19,876,735 shares of its common stock by selling stockholders.

Aclarion, Inc. is registering for resale up to 2.5 million shares of its common stock by White Lion Capital, while also addressing ongoing compliance issues with Nasdaq's minimum bid price and stockholders' equity requirements.

FibroBiologics, Inc. has engaged Maxim Group LLC as its financial advisor and investment banker to provide general financial advisory and investment banking services, including assistance with a potential direct listing or other go-public transactions.

60 Degrees Pharmaceuticals is seeking to raise capital through a unit offering to support its malaria prevention product and expand into new therapeutic areas like tick-borne diseases.

Perfect Moment Ltd. has filed an amendment to its Form S-1 registration statement, primarily to update exhibits related to the underwriting agreement and legal opinions, as it prepares for its initial public offering.

ArriVent BioPharma amends its S-1 filing for an initial public offering of 8.3 million shares, aiming to fund furmonertinib development and pipeline expansion.

Panbela Therapeutics launches a best efforts public offering of common stock and warrants to raise capital and address Nasdaq compliance issues.

CNS Pharmaceuticals is launching a public offering of common stock, pre-funded warrants, and common warrants to fund its clinical trial and for general corporate purposes.

Aptose Biosciences is launching a public offering of common shares and warrants, aiming to raise $9.9 million to support the development of its cancer treatment pipeline.

Processa Pharmaceuticals is launching a public offering to raise capital for a Phase 2 clinical trial of its NGC-Cap drug and for general corporate purposes.

Emerging wireless audio technology company WiSA Technologies, Inc. has filed a registration statement for a new securities offering, aiming to raise capital to sustain operations amid ongoing financial losses and a need for near-term financing.

Xcelerate, Inc. has filed an amended S-1 registration statement detailing its plans for a public offering and subsequent listing on the Nasdaq Capital Market, aiming to fund its healthcare services and products businesses.

Alternus Clean Energy is registering the resale of a substantial amount of its common stock and warrants by existing securityholders.

FlyExclusive, Inc. has filed a registration statement for the resale of shares and warrants by selling stockholders after completing its business combination with EG Acquisition Corp.

Cyclacel Pharmaceuticals has filed a registration statement for the resale of up to 411,969 shares of its common stock, which are issuable upon the exercise of outstanding warrants held by selling security holders.